X

Trial Profile

Phase I/II Clinical Trial of the Combination of Trastuzumab (Herceptin) and 17-allylamino-17-demethoxy-geldanamycin (KOS-953; 17-aag)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 26 May 2008

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tanespimycin (Primary) ; Trastuzumab (Primary)
Indications Advanced breast cancer; HER2 positive breast cancer
Focus Therapeutic Use
Sponsors Kosan Biosciences

Most Recent Events

14 May 2008 Updated results will be presented at the American Society of Clinical Oncolgy 2008 meeting, according to a Kosan media release.
16 Dec 2007 Preliminary results from 20 clinically evaluable patients were presented at the 2007 San Antonio Breast Cancer Symposium held in San Antonio, Texas, USA.
22 Jan 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com